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Abstract:
The inducible cAMP early repressor (ICER) is transcribed from an alternative
intronic promoter (P2) of the CREM gene and functions as powerful repressor of cAMP
induced transcription.

ICER represses the activity of its own promoter, forming a

negative autoregulatory loop. PTH induces ICER expression in osteoblastic cells and
mouse calvariae. To determine the pathways used by PTH to regulate ICER expression,
the activity of a construct containing the ICER 5' regulatory region linked to a luciferase
reporter (CREMP2-Luc238) was analyzed in stably transfected osteoblastic MC3T3-EI
cells.

Cells were treated with pharmacological activators (forskolin, 8-bromo-cAMP,

phorbol myristate acetate (PMA), PTH(3-34) and ionomycin) and a pharmacological
inhibitor (H89), to investigate the signaling pathways that regulate PTH-dependent ICER
promoter activity. To determine whether the state of osteoblast differentiation affects
PTH induction of the ICER promoter, MC3T3-El cells were grown to confluence for 6-7
days, then supplemented with ascorbic acid and assayed for markers of osteoblastic
differentiation at each time point by Northern blot analysis. The cells were treated with
PTH and ICER promoter activity measured. CREMP2-Luc238 expression was induced
by PTH(I-34), FSK, 8-bromo-cAMP, PGE2, but not PMA, ionomycin, or PTH(3-34). In
addition a specific PKA inhibitor, H89, blocked PTH induction of CREMP2-Luc238
activity, suggesting that PTH induces CREMP2-Luc238 expression through the cAMPPKA pathway. Moreover, our data show that the stages of osteoblast differentiation may
not affect PTH induction of CREMP2-Luc238 expression. Therefore, ICER induction
may represent a novel mechanism by which PTH regulates gene expression in
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osteoblastic cells.

Further studies in this area will enhance our understanding of

hormonal regulation of gene transcription in osteoblasts.

Background:
Parathyroid hormone and bone
Parathyroid hormone (PTH) is one of the most important regulators of serum
calcium levels in humans.

It normalizes a low serum calcium level by indirectly

activating the formation and activity of osteoclastic cells to increase bone resorption, as
well as causing many direct changes in the functions of osteoblastic cells [1]. The latter
involves a switch in the phenotype of the osteoblast from one of bone formation to one of
matrix degradation and active participation in the resorption process [2]. Cells of the
osteoblast lineage, not osteoclasts, are the principal skeletal targets of PTH. PTH acts on
osteoblasts, which then transmit a signal to the osteoclast that results in increased bone
turnover.

As a result, PTH-stimulated resorption and osteoclastogenesis require the

presence of osteoblast cells [3]. PTH increases the expression of several mediators
implicated in osteoclastogenesis and resorption, such as interleukin-11 (IL-11),
interleukin-6 (IL-6) [4], prostoglandins [5], and the plasma membrane-bound osteoclast
differentiation factor RANKL [6].
The effect of PTH on bone metabolism depends on the experimental model,
dosage and mode of administration [7]. Continuous exposure of the skeleton to increased
levels of PTH results in high bone turnover and bone loss.

In marked contrast,

intermittent administration of PTH increases net bone formation [8]. However, the exact
mechanism for this anabolic effect is not clear. It is associated with activation of the
lining cells on the surface of the bone and enhanced proliferation and differentiation of
osteoprogenator cells in bone marrow [9]. It has also been suggested that there is an
actual delay in osteoblast apoptosis, the fate of the majority of cells under normal
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conditions. This would prolong the time spent in performing their matrix synthesizing
function, as opposed to osteoclast precursor proliferation, which contributes to the
anabolic effects in rats [10].
Thus, PTH has a diverse effect on osteoblastic cells. Studies of gene expression
in osteoblasts are necessary to determine the mechanism by which PTH regulates both
bone resorption and bone formation, biological processes absolutely necessary for
orthodontic tooth movement.

POE? and bone
Prostaglandins (PGs) are potent and complex regulators of bone metabolism.
Prostaglandins, abundant in bone, are produced primarily by osteoblasts and derived from
phospholipids in the membrane bilayer. They are released in response to direct cellular
damage or by any non-destructive perturbation of the membrane of phospholipid cells, be
it physical, chemical, hormonal or neurohormonal [11].

In orthodontics, the forces

applied to move teeth through bone induce local inflammation, increasing vascular
permeability and cellular infiltration causing lymphocytes, monocytes and macrophages
to infiltrate into the inflammatory tissue where the prostaglandins are released.
Prostaglandins, in tum, activate adenylate cyclase, which induces an increase in the
intracellular levels of cAMP.

This increase in cAMP stimulates the release of

prostaglandins again. Prostaglandin levels appear to be regulated by a negative feedback
mechanism with increased levels inhibiting adenylcyclase activity. They are reported to
promote bone resorption, not only by increasing the number and size of the osteoclast but
also by stimulating the activation of existing osteoclasts [12].
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However, the effects of prostaglandins on bone metabolism are not that clear;
they appear to be quite complex.

Some studies show that prostaglandins enhance

proliferation of osteoblastic cells [13] while others indicate the opposite [14].
Interestingly, Baylink et al. sllowed that the effects of prostaglandins on osteoblast
proliferation are actually biphasic with stimulation at lower concentrations (10.9 M) and
inhibition at higher concentrations (10.6 M).
The data on the effects of prostaglandins on the differentiation of osteoblasts are
more conclusive. Prostaglandins have been shown to clearly enhance differentiation of
osteoblastic progenitors into mature osteoblasts. However, they generally inhibit the
function of mature osteoblasts preventing collagen production [11]. The effects of PGE2
are similar to those of PTH. PGE2 has been shown by many to stimulate bone resorption,
decrease collagen synthesis and cause increased levels of cAMP.

cAMP-PKA signaling pathway
Individual cells of all types of organisms have evolved a mechanism by which
they can sense and respond appropriately to environmental stimuli. The higher the level
of the organism involved, the greater the diversity of signals they can respond to,
including growth factors, hormones, nutrients and sensory input. These signals regulate
cellular differentiation and proliferation.

However, the receiving cell must have the

appropriate receptor and signal transduction pathway to elicit a response [15].
When a ligand such as a growth factor or hormone binds to a receptor on the
plasma membrane, a signal that binding has occurred is received inside the cell and
transduced to other molecules by a second messenger such as cAMP, which is generated
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by the membrane protein AC (adenylate cyclase).

Ligand binding to a cell surface

receptor can stimulate the activity of membrane associated AC converting ATP to cAMP.
cAMP, in turn, binds cooperatively to two sites on the regulatory subunit of protein
kinase A (PKA), causing dissociation of the inactive protein kinase A complex into
active catalytic subunits and regulatory subunits. The catalytic subunits migrate into the
nucleus where they phosphorylate and, thereby, activate transcription factors [16].
Transcription factors are proteins that control the rate of gene expression by integrating
information from promoter sequences and signal transduction pathways.
PTH mediates its effects on bone metabolism by binding to PTH-PTH-related
protein (PTHrP) receptors present on the plasma membrane of osteoblasts. PTH binding
to this receptor stimulates the adenylate cyclase and phospholipase C, thereby activating
primarily the cAMP-PKA pathway, but also the protein kinase C (PKC) and calcium
signaling pathways. Activation of these pathways leads to changes in gene expression by
transcriptional and/or post- transcriptional mechanisms [17].
In eukaryotes, transcriptional regulation activated by the AC signaling pathway is
mediated by the CREB (cAMP response element binding protein)/ATF (activating
transcription factor) family of cAMP responsive transcription factors. cAMP regulation
of gene expression in many types of cells involves the interaction of gene promoter sites
with CREB [18]. CREM, the cAMP response element modulator, is a member of the
CREBIATF family.

This family consists of many members which arise by alternative

splicing and alternative promoter utilization and can act as transcriptional activators and
repressors by binding to cAMP response elements (CRE) in the promoter region of genes.
CRE is an eight base pair palindromic sequence (TGACGTCA).

CREBIATF
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transcription factors contain basic domain/leucine zipper motifs and exhibit a great
functional diversity by binding as heterodimers as well as honlodimers to CREs [2, 5].
CREM is a multiexonic gene that by alternative splicing gives rise to both
activators and repressors of the cAMP- dependent transcription [19]. The CREM gene
encodes two glutamine-rich domains (Q1 and Q2) that are responsible for transcriptional
activation, the phosphorylation box (P-box) or inducible kinase domain and two DNA
binding domains (DBDI and II).

The CREM antagonists

<1, ~,

and y lack the two

glutamine-rich domains. They bind to CREs but do not stimulate basal transcription, thus
behaving functionally as repressors of cAMP-induced transcription.

CREM~,

another

isoform, includes these domains and is a transcriptional activator. However, none of
these isoforms are inducible by activation of the cAMP-signaling pathway.

Inducible cAMP early repressor (ICER)
An inducible CREM transcript encodes a novel isoform called inducible-cAMP
early repressor (ICER) [19, 20]. ICER is a small protein of 120 amino acids with a
predicted molecular weight of about 13.4 kDa. ICER lacks the Q and kinase inducible
domains and is essentially only the DNA binding domain of CREM, consisting of the
leucine zipper and basic region. Therefore, ICER functions as a powerful repressor of
cAMP-induced transcription. ICER is generated by the use of an alternative intronic
promoter, P2. In contrast to the promoter generating all the previously characterized
isoforms (P 1), which is GC rich and not inducible by cAMP, the P2 promoter has a
normal A-T and G-C content and is strongly inducible by cAMP. The P2 promoter
contains two pairs of closely spaced CREs in tandem separated by only three nucleotides.
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This feature makes P2 unique among cAMP regulated promoters and is suggestive of
cooperative interactions among factors binding to these sites [21].

ICER expression

characterizes CREM as an early response gene. Following the induction of CREM by
cAMP, there is a rapid rise in ICER that peaks after 2 hours of stimulation and does not
require de novo protein synthesis.

Significantly, the subsequent decline in ICER

expression, occurring approximately after 5 hours, requires protein synthesis.

ICER

represses its own production via a negative autoregulatory mechanism that involves
binding to its own promoter and blocking transcription[19]. ICER represents the first
transcriptional repressor in the cAMP pathway whose function is regulated primarily by
modulation of its intracellular levels and not by phosphorylation [16].
CRE-binding proteins playa pivotal role in the physiology of the pituitary gland,
spermatogenesis, circadian rhythms and the molecular basis of memory. In the testis
there exists a striking differential regulation of CREM expression according to the
developmental stage.

CREM mRNA is a highly abundant transcript in adult testis,

whereas in prepubertal animals it is expressed at very low levels [16, 22]. In addition,
CREM is expressed with a circadian rhythm in the pineal gland [16, 23]. Analysis reveals
a dramatic day-night regulation, with peak expression occurring during the night.
Experiments indicate that CRE-binding proteins are likely to playa role in the molecular
processes leading to long-term memory [18].
distributed in neuroendocrine tissues.

ICER appears to be predominantly

This information suggests an important role for

ICER in the cAMP regulation of neuroendocrine genes [19].
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Significance to Orthodontics
Orthodontics involves the movement of teeth through bone. It is thought of as
increased bone renl0deling in response to the mechanical force applied to the teeth.
Biologically, the process involves active bone remodeling, bone resorption and bone
deposition.

When a force is applied to a tooth the periodontal cells are compressed

between the tooth root and alveolar bone. These cells secrete bone-resorbing cytokines,
which stimulate osteoclast function and bone resorption [24]. The alveolar bone
surrounding the tooth is remodeled in such a way that the surface under pressure is
resorbed and the bone surface under tension is deposited. The role of bone metabolism,
however, in controlling tooth movement has been considered secondary to the force
applied.

This is largely a result of the difficulty in altering bone metabolism

systemically, in addition to the fact that the force applied is the most easily manipulated
factor [25]. The remodeling of bone that occurs with the orthodontic force is at the local
level in the bone microenvironment. However, remodeling that is regulated with
hormones such as PTH is at the systemic level.
PTH regulates bone metabolism through an osteoblast-mediated mechanism.
PTH increases osteoclastic bone resorption by inducing the production of local mediators
in osteoblastic cells. Thus, since PTH is a potent stimulator of bone resorption, it has
been proposed as a means of accelerating tooth movement in orthodontic treatment[24,
26].

Therefore, it is possible that administration of this bone-resorbing factor may

increase bone-resorbing activity in compressed periodontal tissue.

If PTH is to be

considered as a treatment modality, it is important to understand the molecular pathways
by which PTH stimulates bone resorption. The rapid and transient induction of leER by
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PTH may be a physiological mechanism by which it controls the transcription of genes
involved in bone resorption.

Hypothesis:
PTH, signaling through the cAMP-PKA pathway, induces the expression of the CREMP2
promoter in MC3T3-El cells.

Objectives:
1. To examine regulation of the CREMP2 promoter by PTH in osteoblastic MC3T3-EI
cells and determine the signaling pathway(s) involved.
2. To determine whether the state of osteoblast differentiation of MC3T3-EI cells alters
the PTH response of the CREMP2 promoter.

Research Plan:
1. To examine regulation of the ICER promoter by PTH in osteoblastic MC3T3-EI cells
and determine the signaling pathway(s) involved.
We developed a model system by stably transfecting an ICER promoter-Iuciferase
construct into osteoblastic MC3T3-El cells. Stably transfected cells were treated
with PTH and luciferase activity measured. To investigate the signaling pathways
involved in PTH's induction of ICER transcription, cells were treated with: forskolin
(FSK) and 8-bromo-cAMP (8Br-cAMP), which activate the cAMP pathway, phorbol
myristate acetate (PMA) and PTH(3-34), which activate the protein kinase C pathway
(PKC), and ionomycin, which increases the intracellular levels of Ca2+. We also
treated the cells with PTH and a pharmacological inhibitor of the cAMP pathway,
H89, to investigate the signaling pathways involved.
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2. To determine whether the state of osteoblast differentiation of MC3T3-E1 cells
affects the PTH response on the ICER promoter.
MC3T3-E1 cells were grown to confluence under conditions described in experiment
#1. At day 7, osteocalcin, bone sialoprotein, and type I collagen mRNA, markers of
the osteoblastic differentiation, were measured. Then, ascorbic acid was added to
differentiate the cells. At day 14, markers of osteoblast differentiation including
osteocalcin, bone sialoprotein, and type I collagen mRNA were measured. At each
time point, cells were treated with PTH, and ICER promoter activity measured.

Materials and Methods:
Materials
Synthetic bovine PTH(1-34), bovine PTH(3-34) amide, forskolin (FSK), phorbol
myristate acetate (PMA), 8-bromocyclic AMP (8Br-cAMP), H89 and ionomycin were
purchased from Sigma Chemical Company (St. Louis, MO). Lipofectamine reagent was
purchased from GIBCO BRL (Gaithersburg, MD). PTH was prepared as a stock solution
containing 1 mg/ml BSA containing 0.001 N HCI and diluted in culture medium at least
1000-fold. FSK, PMA and ionomycin were prepared as stock solutions in 100% ethanol
and diluted in culture medium at least 1ODD-fold. 8Br-cAMP was dissolved directly in
the culture medium to a final concentration of 1 mM. The ICER promoter-Iuciferase
construct (CREMP2-Luc238) was kindly provided by Dr. Carlos Molina (UMDNJ-New
Jersey Medical School and Graduate School of Biomedical Sciences, New Jersey). This
construct contains the mouse CREM P2 promoter region from -238/+14 bp with 2
clusters of cAMP-responsive elements (eRE) cloned into the pGL3 luciferase reporter
plasmid (Promega, Madison, WI) (Figure 1).
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Figure 1

Drawing of the CREMP2-Luc238 construct.

A fragment of CREMP2 promoter from -238 to + 14 bp, containing two clusters of
CREs in tandem, was linked to a luciferase reporter.

15

co
(W)

N
(.)
~

-I
I
N

C.

:E

w

a:

o

co

M

N
I

16

Cell Culture
MC3T3-E1 cells stably transfected with CREMP2-Luc238 were plated at 5000
cells/cm2 in 35- or 100-nun tissue culture wells, cultured in a humidified atmosphere of
5% C02 in air at 37° C and fed every 3 days with DMEM supplemented with 10% heatinactivated fetal calf serum (HIFCS), 100 V/ml penicillin and 50 Jlg/ml streptomycin.

Total RNA isolation and Northern blot analysis
Total RNA was extracted by the guanidinium isothiocyanate method of
Chomczynski and Sacchi [27].

MC3T3-E1 cells stably transfected with CREMP2-

Luc238 from three 35-mm wells or one 100-mm plate were washed twice with cold PBS
and lysed with a solution containing 4M guanidinium thiocyanate. RNA was extracted
with H20-saturated phenol/chloroform-isoamyl (24:1); precipitated with an equal volume
of isopropanol, in the presence of 0.2M sodium acetate, pH 4.0, at -20°C. The pelleted
RNA was dissolved in guanidinium thiocyanate solution and precipitated with
isopropanol. The final RNA pellet was washed twice with 80% ethanol, lyophilized,
dissolved in diethylpyrocarbonate-treated water and quantitated by absorbance at 260 nIn.
Twenty micrograms of total RNA was fractionated by electrophoresis on a 1% agarose6% formaldehyde gel and transferred to a GeneScreen Plus hybridization membrane.
Membranes were prehybridized for 3h, hybridized at 42°C or 56°C for 12-16 h with
(32 p )dGTP labeled cDNA probes and exposed to x-ray film at -70°C.
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Transient Transfection
MC3T3-El cells were plated at 250,000 cells per 35 mm dish in DMEM
containing 10% HIFCS, 100D/ml penicillin and 50 J..lg/ml streptomycin. When cells
reached 60-80% confluence (overnight), transient transfection was performed using
DOTAP reagent (Boehringer Mannheim, Indianapolis, IN). 1 J..lg/reaction of PGL3 and
CREMP2-Luc238 constructs were diluted with HEPES and mixed with DOTAP reagent,
which was also diluted with HEPES.

Cells were incubated with the DOTAP-DNA

mixture at 37°C for 5-6h. The DOTAP-DNA mixture was aspirated at the end of the
incubation period, and fresh DMEM containing 10% HI-FCS, 100D/ml penicillin and 50
).!g/ml streptomycin was added for 48 h prior to effector treatments.

Luciferase assay
The induction of CREMP2-Luc238 by the effectors was measured for luciferase
activity. MC3T3-EI cells stably transfected with CREMP2-Luc238 were grown to
confluence in 35-mm wells as described above and treated with PTH and effectors for 4
h. In brief, the cells were washed twice with cold PBS and lysed in 200 JlI of a lysis
buffer containing 25 mM Tris-phosphate (pH 7.8), 2 mM dithiothreitoI, 2 mM 1,2diaminocyclohexane-N, N, N', N-tetraacetic acid, 10% glycerol, and 15% Triton X-IOO.
The cell lysates were transferred to Eppendorf tubes and centrifuged for 30 sec. Ten
microliters of each supernatant were assayed using a commercially available luciferase
kit (Promega, Madison, WI), which was quantitated on a Berthold LB 9501/16luminator
(Wallac, Gaithersburg, MD).

Luciferase activity was normalized to protein content,

which was measured using the indicator bicinchoninic acid [28].
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Statistics
Data were analyzed using a one-way ANOVA, and statistical differences between
the groups were determined using the Student-Newman-Keuls post hoc test.

Results:

Specific Aim J :

To examine regulation of the CREMP2 promoter by PTH in
osteoblastic MC3T3-EJ

cells

and determine

the

signaling

pathway(s) involved

Two populations of stably transfected MC3T3-EI cells were obtained.

Each

population contained multiple individual clones of stably transfected cells.
To study the signaling pathways involved in the PTH induction of CREMP2
promoter activity, stably transfected MC3T3-EI cells were treated for 4 h with the
following signaling molecules: IO-8 M bovine PTH(I-34), IO-5 M forskolin (FSK), IO-6M
PGE2, and 3 mM 8-bromo-cAMP (8Br-cAMP), which activate the cAMP pathway, and
10-6M ionomycin, which increases intracellular levels of Ca2+.

In the following

experiments, the fold-induction of each effector was calculated as the ratio of effector
treatment vs. vehicle. The fold induction of the control group was set as 100% and the
experimental groups were expressed as percentage of the control. All experiments were
repeated at least twice with similar results.
In the first population, FSK and 8Br-cAMP significantly induced the CREMP2Luc238 activity (567±130% and 346.5±19%, respectively, of the control group) (Figure
2).

PTH(I-34) and PGE2 induced CREMP2-Luc238 activity to 170.5±47.5% and

150.5±31.5%, respectively, while ionomycin did not induce CREMP2-Luc238 (Figure
2). Population 2 showed similar results (Figure 3). In addition, Population 2 cells were
also treated with IO-7M PMA for 4h, which did not induce CREMP2-Luc238. (Figure 3).
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These data suggested that CREMP2-Luc238 activity was induced mainly through the
cAMP-PKA pathway.

To determine the involvement of the PKA pathway in the induction of the
CREMP2-Luc238 by PTH, stably transfected MC3T3-EI cells were pretreated with 40
J.!M H89, a pharmacological inhibitor of the cAMP-PKA pathway, for 1 h followed by
either addition of vehicle or

la-8M PTH(I-34)

for 4 h. PTH caused a significant 1.65-

fold induction of CREMP2-Luc238 (Figure 4). However, pretreatment with H89 blocked
PTH induction to the level of the control suggesting that cAMP-PKA pathway is
involved in PTH induction ofCREMP2-Luc238 activity.

To further confirm that H89 is a specific inhibitor of the cAMP-PKA pathway,
stably transfected MC3T3-El cells were pretreated with 40 J.!M H89 for 1 h followed by
either addition of vehicle or IO- 5M forskolin (FSK), for 4 h. FSK caused a significant
induction of CREMP2-Luc238 to 371.5±63.5% of the control group (Figure 5).
However, pretreatment with H89 blocked FSK induction to the level of the control.
Population 2 showed similar results as Population 1 suggesting that cAMP-PKA pathway
is involved in FSK induction ofCREMP2-Luc238 activity.
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To study the signaling pathways involved in the induction of CREMP2-Luc238
expression by PTH, stably transfected MC3T3-El cells were treated with PTH(1-34) or
an N-terminal truncated PTH analog, PTH(3-34), which lacks the first two amino acids
that are critical for activating the cAMP-PKA pathway [29, 30]. Since PTH(3-34) is in
amide form, PTH-NH2, was used for comparison. PTH(1-34) and PTH-NH2 similarly
induced

CREMP2-Luc238 expression (170.5±47.5% and

respectively).

165±14% of control

In contrast, PTH(3-34) did not induce CREMP2-Luc238 (l09±20% of

control) (Figure 6). Population 2 showed similar results. These data suggest that PTH
induces CREMP2-Luc238 expression primarily through the cAMP-PKA pathway.
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Figure 2

cAMP activators induce CREMP2-Luc238 activity in stably transfected
MC3T3-E1 cells.

MC3T3-E1 cells stably transfected with CREMP2-Luc 238 (population 1) were
treated with 10 nM PTH, 10 JlM FSK, 1 JlM PGE2 , 3 mM 8-bromo-cAMP, and 1
JlM ionomycin for 4 h. Cell lysates were prepared and assayed for luciferase
activity as described in Materials and Methods. Each value is a meall ± SEM of 2
to 5 separate experiments, each performed with triplicate determinations in each
group.

* Significant difference (p<.05) from control.
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Figure 3

FSK and PGE2 induce CREMP2-Luc238 activity in stably transfected
MC3T3-El cells.

MC3T3-El cells stably transfected with CREMP2-Luc238 (population 2) were
treated with 10 nM PTH, 10 J.lM FSK, 1 J.lM PGE2, 100 nM PMA, and 1 J.lM
ionomycin for 4 h. Cell lysates were prepared and assayed for luciferase activity
as described in Materials and Methods. Each value is a mean

±

SEM of 2 to 5

separate experiments, each performed with triplicate determinations in each
group.

* Significant difference (p<.05) from control.
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Figure 4

A specific PKA inhibitor, H89, completely inhibits CREMP2-Luc238
activity in stably transfected MC3T3-El cells.

MC3T3-El cells stably transfected with CREMP2-Luc238 (population 1) were
pre-treated with 40 J.!M H89 for 1 h and subsequently treated with lO-8M PTH(l34) lO-5M for 4 h. Ceillysates were prepared and assayed for luciferase activity
as described in Material and Methods. Each value is a mean ± SEM of an
experiment with triplicate determinations in each group.

a

Significant difference

(P<.Ol) from control; b Significant difference (P<.Ol) from PTH(1-34).
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Figure 5

A specific PKA inhibitor, H89, inhibits CREMP2-Luc238 activity in the
second population of stably transfected MC3T3-E1 cells.

MC3T3-E1 cells stably transfected with CREMP2-Luc238 (population 1) were
pre-treated with 40 J-lM H89 for 1 h and subsequently treated with 10-5M forskolin
(FSK) for 4 h. Ceillysates were prepared and assayed for luciferase activity as
described in Materials and Methods. Each value is a mean ± SEM of 2 separate
experiments with triplicate determinations in each group. a Significant difference
(P<.Ol) from control; b Significant difference (P<.Ol) from FSK.
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Figure 6

PTH(3-34) does not induce CREMP2-Luc238 expression in stably

transfected MC3T3-El cells.
MC3T3-El cells stably transfected with CREMP2-Luc238 (population 1) were
treated with 10 nM PTH(I-34), 10 nM PTH(I-34) amide, and 10 nM PTH(3-34) for
4 h. Ceillysates were prepared and assayed for luciferase activity as described in
Materials and Methods. Each value is a mean ± SEM of 2 separate experiments,
each performed with triplicate determinations in each group.

31

PIH(1-34)

PIH(3-34)

a

100

200

Percentage of Control
(% )

33

Since ascorbic acid did not seem to be necessary for differentiation of stably
transfected MC3T3-El cells, a time course was performed without ascorbate to examine
osteoblast mRNA markers in stably transfected MC3T3-El cells by Northern blot
analysis and PTH induction of CREMP2-Luc238.

Northern blot analysis showed that Collal nlRNA was present on day 3 and
remained constant up to day 14. BSP mRNA did not appear until day 7, peaked at day 10
and then remained constant. OC mRNA was not present on day 3, appeared on day 7 and
was greatly increased on day 14 (Figures 10 and 11).

CREMP2-Luc238 expression was induced by PTH at all time points. The level of
induction by PTH ranged from 2- to 4-fold throughout the entire experiment period
(Figure 12). Note, however, that the baseline luciferase activity was constant until day
14, and then decreased at later time points.

These data suggested that the stage of

osteoblast differentiation may not determine the PTH response of stably transfected
CREMP2-Luc238 cells.
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Figure 7

Ascorbic acid is not required for the expression of osteoblastic
differentiation markers in stably transfected MC3T3-E1 cells.

Osteoblastic MC3T3-El cells (population 1) were plated at 5000 cells/cm2 • On day
7, the medium was changed and cells were cultured in medium with or without
ascorbic acid (50 ).lg/ml) for another 7 days. Total RNA isolation was performed on
day 7 and 14 subjected to Northern blot analysis.
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Figure 8

Ascorbic acid is not required for the expression of osteoblastic
differentiation markers in stably transfected MC3T3-E1 cells.

Osteoblastic MC3T3-E1 cells (population 1) were plated at 5000 cells/cm2 • On
day 7, the medium was changed and cells were cultured in medium with or
without ascorbic acid (50 J.!g/ml) for another 7 days. RNA was extracted on day 7
and 14 and subjected to Northern blot analysis.
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Figure 9

The stage of differentiation of stably transfected MC3T3-El cells
with CREMP2-Luc238 does not affect the PTH response

A parallel set of stably transfected MC3T3-El cells was cultured as described in
Figures 7 and 8. Cells were treated with either 10 nM PTH(I-34) or vehicle for 4
h. Luciferase was assayed on days 7 and 14. Each value is a mean

±

SEM of 2

separate experiments, each performed with triplicate determinations in each
group. *Significant difference (p<.05) from control.
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Figure 10

Stably transfected MC3T3-El

cells expressed osteoblastic MRNA

markers on day 14 in the absence of ascorbic acid.

A time course was performed without ascorbic acid to determine the expression of
osteoblastic nlarkers in stably transfected MC3T3-El cells by Northern blot
analysis.
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Figure 11

Stably transfected MC3T3-El cells expressed osteoblastic differentiation
markers on day 14 in the absence of ascorbic acid.

A time course was performed without ascorbic acid to determine the
expression of osteoblastic n1arkers in stably transfected MC3T3-El cells by
Northern blot analysis.
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Figure 12

The stage of osteoblast differentiation may not determine the PTH
response of stably transfected CREMP2-Luc238 cells.

A parallel set of stably transfected MC3T3-El cells was cultured as those
described in Figures 10 and 11. Cells were treated with either 10 nM PTH(I-34)
or vehicle for 4 h and luciferase activity was assayed on day 3, 7, 10 and 14.
Each value is a mean ± SEM of 2 separate experiments, each performed with
triplicate determinations in each group.
control.

*Significant difference (p<.05) from
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Discussion:

The goals of these experiments were to 1) examine the regulation of CREMP2Luc238 promoter by PTH in osteoblastic MC3T3-E1 cells and determine the signaling
pathway(s) involved and 2) determine whether the state of osteoblast differentiation of
MC3T3-E1 cells alters the PTH response of the CREMP2-Luc238 promoter. Our data
demonstrate that PTH regulates the CREMP2-Luc238 promoter through the cAMP-PKA
pathway.
PTH exerts its biological effects by binding to the PTH/PTHrP receptor that is
found predominantly, but not exclusively, in cells of the osteoblast lineage [31]. Upon
PTH binding, the PTH/PTHrP receptor, a G protein-coupled transmembrane receptor,
activates many signaling pathways causing an increase in intracellular messengers such
as cAMP [32] and diacylglycerol [33], which activate the protein kinase A (PKA) and
protein kinase C (PKC) signaling pathways, respectively. A third second messenger,
inositol 1,4,5-triphosphate [34], is also activated leading to an increase in intracellular
free calcium levels, which can also activate protein kinase C. However, cAMP-PKA is
probably the predominant pathway mediating the PTH-regulated gene expression in
osteoblastic cells [2, 17, 35, 36].
Since PTH can activate multiple signaling pathways, we used pharmacological
activators and inhibitors of several signaling pathways by which PTH regulates
CREMP2-Luc238 expression. Agents that activate the cAMP-PKA pathway such as
FSK, 8-bromo-cAMP and PGE2 increased CREMP2-Luc238 expression. PMA, which
activates the PKC pathway, and ionomycin, which works through the inositol 1,4,5-
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triphosphate system to increase the intracellular levels of calcium, also activating the
PKC pathway, did not increase CREMP2-Luc238 expression. H89, a PKA specific
inhibitor, significantly reduced FSK- and PTH-induced CREMP2-Luc238 activity. FSK
induced PTH(3-34), an analog that lacks the two N-terminal amino acids of PTH and
signals through the PKC pathway and intracellular calcium, but does not activate the
cAMP-PKA pathway [29, 30] was unable to induce CREMP2-Luc238 expression.
Collectively, the data suggest that PTH regulates CREMP2-Luc238 expression in
osteoblastic MC3T3-E1 cells by the cAMP-PKA pathway. It is important to recognize
that utilization of other pathways has been suggested for PTH-induced osteoclast-like cell
formation, bone resorption, and PTH-mediated changes in osteoblastic proliferation [17].

As stated previously, PTH exerts its biological effects by binding to the
PTHIPTHrP receptor. The PTHIPTHrP receptor is a member of a family of G proteinlinked, 7 transmembrane domain receptors and binds with equal affinity to PTH and
PTHrP. Although it is generally accepted that cells of the osteoblast lineage are the
primary targets for PTH action in bone, it is not clear at what stage the osteoblastic cell
begins to express surface receptors for PTH [37].

Rouleau et al indicated that an

undifferentiated stromal cell had the greatest receptor binding sites, but others suggest
that the mature osteoblast is more responsive to PTH [37]. McCauley and colleagues
found that the normal differentiation of MC3T3-E1 preosteoblastic cells was
accompanied by a progressive increase in the steady-state mRNA levels for the
PTHIPTHrP receptor. The PTH/PTHrP receptor was low during cell proliferation and
increased once cells began to differentiate. Thus, one would conclude that a more mature
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osteoblast would be more responsive to PTH than a less differentiated osteoblastic cell.
However, our results do not concur with this finding. PTH induced CREMP2-Luc238
expression by an average of 3-fold on day 7. Further culture and differentiation of the
cells did not affect the CREMP2-Luc238 response to PTH stimulation. Similar results
were found when the time course was performed without ascorbate. In this experiment
CREMP2-Luc238 expression was induced 3-fold by PTH on day 3 and remained at that
level throughout the 14 day experimental period. These data suggest that the stage of
osteoblast differentiation may not determine the PTH response of stably stransfected
CREMP2-Luc238 cells.

Several studies report that ascorbic acid (AA) is necessary for the in vitro
differentiation of a variety of cell types, including adipocytes, myoblasts, chondrocytes,
odontoblasts, and osteoblasts. It is thought that the addition of AA stimulates the initial
deposition of collagenous extracellular matrix, followed by the induction of specific
genes associated with the osteoblast phenotype such as the bone/liver/kidney isozyme of
alkaline phosphatase and osteocalcin.[38]. However, our study did not show that AA was
necessary for the differentiation of the stably transfected osteoblastic MC3T3-E1 cells.
As stated previously, we found by Northern blot analysis that osteoblast mRNAs were
expressed on day 7, and the expression level increased on day 14 in the presence or
absence of AA.

However, an important factor seems to be the plating density.

Preliminary results showed that on day 7 in the presence of AA and a plating density of
5,000 cells/cm2 differentiation was enhanced. Furthermore, a plating density of 15,000
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cells/cm2 showed greater differentiation than the 5,000 cells/cm2, suggesting that plating
density plays a role in osteoblastic cell differentiation (unpublished observation).
In addition, when a time course was performed without AA, Northern blot
analysis revealed that Col1a1 mRNA was present on day 3 and remained unchanged up
to day 14. BSP mRNA did not appear until day 7, peaked at day 10 and decreased
slightly by day 14. Osteocalcin mRNA was not present on day 3, appeared on day 7 and
was highly expressed on day 14. We can conclude from these data that the length of
culture plays a role in differentiation. In conclusion, our data show that AA is not
necessary for the differentiation of CREMP2-Luc238 stably transfected cells, but the
plating density and length of culture playa role.

As mentioned previously, PGE2 binds to cell surface receptors and activates the
cAMP-PKA pathway [39].

PGE2 induces ICER mRNA expression by reverse

transcriptase-polymerase chain reaction (RT-PCR) in MC3T3-EI cells and neonatal
mouse calvaria [40] as well as playing a role in bone metabolism [11]. The cycle of bone
turnover is divided into periods of activation, resorption and formation. It was reported
for the first time by Klein and Raisz in 1970 that prostaglandins promote bone resorption
by acting on osteoclasts. Such insight into the bone remodeling cycle is very important in
orthodontic therapy.

Over the years, orthodontics has evolved with advancing

technology that has produced appliances and new materials that have resulted in
improved results and reduced treatment time.

Successful bone remodeling would

produce less histological damage and pain, enhanced tooth movement, shorter treatment
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periods, and more stable results. However, there may be a biological threshold beyond
which bone remodeling and, therefore, tooth movement cannot occur any more quickly.
Studies of factors, such as prostaglandins, which decrease the formation period of
the bone remodeling cycle on the pressure side during tooth movement and use activation
and resorption periods for efficient bone resorption, are considered to be of particular
significance to contemporary orthodontics [12]. Yamasaki et al [41, 42] have shown that
the rate of orthodontic tooth movement increases with local injection ofPGE2 in monkeys
and local injections of PGE 1 in humans. Kawata and Yamashita reported that pasting
PGF2a on the oral mucosa of patients resulted in accelerated tooth movement and
alleviated pain during the process [12]. Chao et al reported that PGE2 increases the total
number of osteoclasts and the osteoclastic-resorptive activity during orthodontic tooth
movement [11]. In addition, prostaglandin antagonists have been shown to decrease the
rate of tooth movement by inhibiting the increase of osteoclasts on the resorptive surface
[43] and the differentiation of osteoblasts on the bone-forming surface [44].
Consequently, the future of orthodontics may lie in improving the rate of bone
remodeling. PGE2 , in spite of its short-term local effects [11], may be useful in future
clinical orthodontic treatment by its local administration combined with tooth movement.
The combination could possibly lead to increased rates of bone remodeling, tooth
movement, and subsequently, treatment time.

The reduction in treatment time may

potentially minimize the possible side effects of orthodontic treatment such as enamel
decalcifications, periodontal disease, and root resorption.

Along the cutting edge of

technology, a more complete understanding of how prostaglandins regulate bone
formation and resorption may lead to the development of new therapies.
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